Product Description
PXL770 is a novel drug candidate that directly activates adenosine monophosphate-activated protein kinase (AMPK); Based on its central metabolic role, we believe that targeting AMPK offers the opportunity to pursue a wide range of indications to treat chronic metabolic diseases, including diseases that affect the liver, such as NASH and rare metabolic disorders (e.g. adrenoleukodystrophy). (Sourced from: https://www.poxelpharma.com/en_us/pipeline/nash)
Mechanisms of Action: AMPK Activator
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: Fast Track - AdrenoleukodystrophyOrphan Drug - AdrenoleukodystrophyOrphan Drug - Kidney Diseases|Polycystic Kidney, Autosomal Dominant *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Poxel
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Fatty Liver, Alcoholic|Non-alcoholic Fatty Liver Disease|Adreno-myeloneuropathy|Adrenoleukodystrophy
Phase 1: Fatty Liver, Alcoholic|Non-alcoholic Fatty Liver Disease|Type 2 Diabetes|Non-alcoholic Steatohepatitis|Healthy Volunteers|Hepatitis, Alcoholic
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT05441904 |
PXL770-009 | P1 |
Completed |
Hepatitis, Alcoholic|Fatty Liver, Alcoholic|Non-alcoholic Steatohepatitis |
2021-03-29 |
2022-07-02 |
Primary Endpoints|Treatments |
|
NCT03950882 |
PXL770-003 | P1 |
Completed |
Fatty Liver, Alcoholic|Non-alcoholic Fatty Liver Disease |
2020-03-29 |
2% |
2021-06-12 |
|
NCT03886103 |
PXL770-005 | P1 |
Completed |
Healthy Volunteers |
2019-03-15 |
|||
NCT03395470 |
PXL770-002 | P1 |
Completed |
Type 2 Diabetes |
2018-03-16 |
55% |
2019-03-22 |
Treatments |
NCT05146284 |
X-ALD or ALD | P2 |
Withdrawn |
Adreno-myeloneuropathy|Adrenoleukodystrophy |
2024-09-01 |
76% |
2024-12-17 |
Patient Enrollment|Primary Endpoints|Treatments|Trial Status |
2021-006223-18 |
START770 | P2 |
Terminated |
Adreno-myeloneuropathy |
2022-07-29 |
2025-05-06 |
Treatments|Trial Status |
|
NCT03763877 |
PXL770-004 | P2 |
Completed |
Fatty Liver, Alcoholic|Non-alcoholic Fatty Liver Disease |
2020-08-03 |
19% |
2021-10-29 |
Primary Endpoints |